Building on its banner pacts with GlaxoSmithKline and upstart Tarsa Therapeutics, Unigene Laboratories ($UGNE) has joined forces with Danish biotech Nordic Bioscience to develop Unigene's oral peptide drugs in the big-time diseases type 2 diabetes, osteoarthritis and osteoporosis. On the top of that deal, Nordic Chairman Dr. Claus Christensen is supplying up to $6 million ($1.5 million to start) in equity investment through a foundation. The deal and investment fuel Unigene CEO Ashleigh Palmer's mission of rebooting the drug-delivery specialist with a pipeline of novel peptide drugs that can be taken orally rather than given via injection like most protein therapies. Article